Geoffrey McDonough - Swedish Orphan CEO
| BIOVF Stock | USD 25.00 0.00 0.00% |
CEO
Dr. Geoffrey McDonough, M.D. no longer serves as President and Chief Executive Officer of Swedish Orphan Biovitrum AB effective as of July 1, 2017. He has held the position since August 15, 2011. He is also Board member of Zafgen and PTC Therapeutics. He previously served for Genzyme Corporation in the United States from 2002, where he has over the years held such roles as Senior Vice President and General Manager, Personalized Genetic Health Senior Vice President, Global Business Unit Leader, LSD Therapeutics, and most recently, President of Europe, Middle East, and Africa . Prior to joining Genzyme, he worked as a pediatrician in the United States, and was also President, and Cofounder of Catalyst Medical Solutions Inc. He graduated from Harvard Medical School with a Medical Doctor degree. He holds a Bachelor of Arts in Philosophy and a BS in Biology degrees from the University of North Carolina. since 2011.
| Age | 44 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 46 86 97 20 00 |
| Web | https://www.sobi.com |
Swedish Orphan Management Efficiency
The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Janet Hall | Guardion Health Sciences | 65 | |
| Nikhil Lalwani | ANI Pharmaceuticals | 46 | |
| Mark Strobeck | Rockwell Medical | 53 | |
| Venkata MBA | Dr Reddys Laboratories | 55 | |
| Patrick Aghanian | Dr Reddys Laboratories | 55 | |
| David RPh | Evoke Pharma | 60 | |
| Scott Tarriff | Eagle Pharmaceuticals | 64 | |
| James Hall | Lifecore Biomedical | 61 | |
| M Ramana | Dr Reddys Laboratories | 52 | |
| David Moatazedi | Evolus Inc | 46 | |
| Murthy Simhambhatla | Evolus Inc | 51 | |
| Arthur Przybyl | ANI Pharmaceuticals | 61 | |
| Jack Zhang | Amphastar P | 71 | |
| Frank Lee | Pacira Pharmaceuticals | 56 | |
| David Gonyer | Evoke Pharma | 60 | |
| Stuart Paul | Rockwell Medical | 58 | |
| MARC KIKUCHI | Dr Reddys Laboratories | 51 | |
| Gil Efron | Kamada | 50 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 |
Swedish Orphan Biovitrum Leadership Team
Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lennart Johansson, Director | ||
| Thomas Larsen, Head Relations | ||
| Rami Levin, Head of North America | ||
| Dennis Pedersen, Senior Vice President Human Resources | ||
| Armin MD, Head Affairs | ||
| Alan Raffensperger, COO and Sr. VP | ||
| Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel | ||
| BoGunnar Rosenbrand, Director, Employee Representative | ||
| Adine Axen, Independent Director | ||
| Hakan Bjorklund, Independent Chairman of the Board | ||
| Cecilia Forberg, Vice President Head of Project and Portfolio Management | ||
| Stephen James, Vice President Head of Drug Design and Development | ||
| Bo Hansen, Chairman of the Board | ||
| Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs | ||
| Henrik Stenqvist, Chief Officer | ||
| David Allsop, Director | ||
| Torbjorn Hallberg, General Counsel and Head of Legal Affairs | ||
| Christine Wesstrom, Head Operations | ||
| Theresa Heggie, Independent Director | ||
| Torbjrn Hallberg, G HR | ||
| Hans Wigzell, Independent Director | ||
| Annette Clancy, Independent Director | ||
| Paula Treutiger, Head of Communications & Investor Relations | ||
| Trista Morrison, Vice President - Communications for North America | ||
| Daniel Rankin, Head Devel | ||
| Kirsti Gjellan, Senior Vice President Manufacturing Operations | ||
| Jorgen Winroth, Head of Investor Relations and VP | ||
| Milan Zdravkovic, Senior Vice President Head of Research & Development | ||
| Norbert Oppitz, Head of Specialty Care | ||
| Hans Schikan, Independent Director | ||
| Konstantina Karampela, Director Operations | ||
| Helena Saxon, Director | ||
| Anne Schuermans, Head of Technical Operations | ||
| Anders Edvell, Head of Marketing and Sales | ||
| Sofiane Fahmy, Head of Southern and Western Europe & North Africa | ||
| Pablo Mora, Head Access | ||
| Philip Wood, Head of Haemophilia | ||
| Geoffrey McDonough, CEO | ||
| Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer | ||
| Fredrik Wetterlundh, Head of Human Resources | ||
| Amy Pott, Head of North America | ||
| Birgitte Volck, Senior Vice President Chief Medical Officer | ||
| MatsOlof Wallin, CFO, Senior Vice President | ||
| Stefan Fraenkel, Vice President Head of Corporate Development | ||
| Hege Hellstrom, Head of EMENAR | ||
| Catarina Larsson, Director, Employee Representative | ||
| Anders MD, Head Officer | ||
| Elisabeth Svanberg, Director | ||
| Christian Dreger, Head of Northern Europe, Middle East & Russia | ||
| Wills HughesWilson, Senior Vice President and Chief Patient Access Officer | ||
| Guido Oelkers, President CEO | ||
| Pia Axelsson, Director, Employee Representative | ||
| Jeffrey Jonas, Independent Director | ||
| Matthew Gantz, Director | ||
| Pia Axelson, Director, Employee Representative |
Swedish Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.14 % | |||
| Current Valuation | 7.05 B | |||
| Shares Outstanding | 295.99 M | |||
| Shares Owned By Insiders | 4.00 % | |||
| Shares Owned By Institutions | 70.55 % | |||
| Price To Earning | 20.33 X | |||
| Price To Book | 2.58 X | |||
| Price To Sales | 3.68 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Swedish Orphan in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Swedish Orphan's short interest history, or implied volatility extrapolated from Swedish Orphan options trading.
Pair Trading with Swedish Orphan
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Swedish Orphan position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Swedish Orphan will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Swedish Orphan could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Swedish Orphan when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Swedish Orphan - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Swedish Orphan Biovitrum to buy it.
The correlation of Swedish Orphan is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Swedish Orphan moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Swedish Orphan Biovitrum moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Swedish Orphan can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Swedish Orphan Biovitrum. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Swedish Pink Sheet analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |